FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Prostate Cancer

Therapeutic area intelligence for Prostate Cancer with 49 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 49
Catalysts: 0
Companies: 10

Companies

Amgen →

Aragon Pharmaceuticals →

Aragon Pharmaceuticals, Inc. →

Assets

Recent signals(49)

CompetitiveAugust 5, 2026

Advancements in Prostate Cancer Diagnostics: AI and Liquid Biopsies Show Promise

Innovations in prostate cancer diagnostics include PSMA-directed imaging and AI-driven methods, enhancing lesion detection.

ClinicalAugust 4, 2026

HRS-5041 Tablets Show Promise in Advanced Prostate Cancer Therapy

A study is underway to assess the efficacy and safety of HRS-5041 tablets in combination with antitumor therapy for advanced prostate cancer.

ClinicalAugust 3, 2026

Phase II Trial of Carboplatin in Metastatic Prostate Cancer with HR Pathway Alterations

A phase II trial is underway to assess carboplatin's efficacy in metastatic castration-resistant prostate cancer with HR pathway gene alterations.

ClinicalAugust 2, 2026

Phase I/II Trial of Olaparib and Radium-223 in Advanced Prostate Cancer

This trial is investigating the safety and efficacy of olaparib in combination with radium-223 for patients with metastatic castration-resistant prostate cancer.

ClinicalAugust 1, 2026

Phase II Trial of Cabazitaxel, Carboplatin, and Cetrelimab for Aggressive Variant Prostate Cancer

A phase II trial is investigating the combination of cabazitaxel, carboplatin, and cetrelimab followed by niraparib in patients with metastatic aggressive variant prostate cancer.

ClinicalJuly 31, 2026

AZD0516 Study for Metastatic Prostate Cancer Initiated

A study has been initiated to evaluate the safety and tolerability of AZD0516 in metastatic prostate cancer patients.

ClinicalJuly 29, 2026

Study on Resistance Mechanisms in Metastatic Castration Resistant Prostate Cancer with 177Lu-PSMA

This clinical trial investigates resistance mechanisms to 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer using image-guided biopsies.

ClinicalJuly 29, 2026

AI vs Radiologist in Prostate Cancer Detection: The PRIMER Trial

The PRIMER trial compares an MRI-based AI approach to traditional radiologist readings for prostate cancer detection.

ClinicalJuly 28, 2026

Study on Combining Focal Prostate Ablation with Androgen Deprivation Therapy

A clinical trial is investigating the safety and effectiveness of combining focal prostate ablation with androgen deprivation therapy.

ClinicalJuly 28, 2026

Novartis initiates Phase Ib/II study of AMO959 in mCRPC with AAA617 and ARPI

Novartis is conducting Phase Ib/II study to evaluate AMO959 combined with AAA617 and ARPI in mCRPC patients.

RegulatoryJuly 24, 2026

FDA Grants Priority Review for TALZENNA Plus XTANDI in Metastatic Prostate Cancer

The FDA has accepted a supplemental New Drug Application for TALZENNA in combination with XTANDI for metastatic castration-sensitive prostate cancer, supported by Phase 3 TALAPRO-3 trial data.

ClinicalJuly 21, 2026

Janssen's Apalutamide Study Targets mCRPC in Chinese Patients

A study is underway to evaluate the pharmacokinetics and safety of apalutamide in Chinese patients with metastatic castration-resistant prostate cancer.

ClinicalJuly 20, 2026

Efficacy Study of Apalutamide in High-risk Prostate Cancer Underway

A study is assessing the efficacy of apalutamide combined with GnRH agonist in high-risk prostate cancer patients undergoing radiation therapy.

ClinicalJuly 20, 2026

NCI and Lantheus Test PMSA-Based PET Imaging for High-Risk Prostate Cancer

A clinical trial is underway to evaluate the effectiveness of PMSA-based PET/CT imaging in predicting prostate cancer recurrence post-surgery.

ClinicalJuly 20, 2026

Clinical Trial Evaluates AI Communication Aid in Prostate Cancer Care

A clinical trial is assessing the efficacy of LLM-assisted communication in reducing psychological distress in prostate cancer patients compared to standard care.

ClinicalJuly 20, 2026

Phase II Study of Adaptive SBRT for Localized Prostate Cancer Initiated

A phase II international multicenter study is evaluating adaptive stereotactic body radiotherapy for localized prostate cancer.

ClinicalJuly 20, 2026

Janssen's Apalutamide Study Targets High-Risk Prostate Cancer Pre-Radical Prostatectomy

A study is underway to evaluate apalutamide combined with ADT in high-risk prostate cancer patients prior to radical prostatectomy.

ClinicalJuly 19, 2026

AI-Enhanced MRI Techniques May Improve Prostate Cancer Diagnosis

A study is underway to evaluate the integration of advanced MRI and AI techniques for better prostate cancer classification.

ClinicalJuly 19, 2026

Study on Real-world Use of Darolutamide in Metastatic Hormone-sensitive Prostate Cancer

A study sponsored by Bayer will analyze real-world data on darolutamide and other ARPIs for mHSPC treatment.

CompetitiveJuly 19, 2026

Astellas Pharma's ASP5541 Phase 2 Study in Advanced Prostate Cancer Underway

A Phase 2 study is evaluating ASP5541, an injectable form of abiraterone acetate, in men with advanced prostate cancer.

ClinicalJuly 19, 2026

Cost-effectiveness of MRI and PET/CT in Prostate Cancer Staging Reevaluated with New Phase 3 Data

Recent Phase 3 trials have provided updated data on the cost-effectiveness of ferumoxtran-enhanced MRI and PSMA-PET/CT compared to ePLND for nodal staging in prostate cancer.

ClinicalJuly 19, 2026

Novel Imaging Biomarker PPAT Thickness Predicts Prostate Cancer in Gray Zone Patients

Normalized periprostatic adipose tissue thickness is introduced as a novel imaging biomarker for predicting prostate cancer in patients with PI-RADS score 3 and PSA levels of 4-10 ng/mL.

ClinicalJuly 17, 2026

Link Between Graves' Disease and Prostate Cancer Explored Through Bioinformatics

The study suggests a potential causal association between Graves' disease and increased risk of prostate cancer, highlighting shared immune mechanisms.

ClinicalJuly 13, 2026

IL-15 Superagonist N-803 Combined with Vaccine ETBX-071 in Recurrent Prostate Cancer Trial Launched

A clinical trial is underway to evaluate the efficacy of N-803 alone and in combination with ETBX-071 in patients with biochemically recurrent prostate cancer post-radiation.

ClinicalJuly 13, 2026

Genentech's GDC-1261 Study Targets Advanced Prostate Cancer Safety and Activity

Genentech is conducting a study to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-1261 in advanced or metastatic prostate cancer.

ClinicalJuly 10, 2026

Pembrolizumab Plus Enzalutamide Trial in mCRPC Shows Promise for Overall Survival

A study is underway to evaluate the efficacy of pembrolizumab combined with enzalutamide in mCRPC patients.

ClinicalJuly 8, 2026

Bayer's Study on Darolutamide in Advanced Prostate Cancer to Assess Real-World Effectiveness

Bayer is conducting a multicenter observational study to evaluate darolutamide's effectiveness in metastatic hormone-sensitive prostate cancer.

ClinicalJuly 8, 2026

Study on JNJ-56021927 and Abiraterone in Metastatic Prostate Cancer

The study aims to evaluate drug-drug interactions and safety of JNJ-56021927 with abiraterone acetate and prednisone.

ClinicalJuly 7, 2026

Bayer's Study on ARPI Use in mHSPC Patients in Australia Aims to Inform Clinical Practice

Bayer is conducting a retrospective observational study to analyze real-world data on Androgen Receptor Pathway Inhibitors in men with metastatic hormone-sensitive prostate cancer in Australia.

ClinicalJuly 2, 2026

Pilot Study on Neoadjuvant Dapagliflozin in High-Risk Prostate Cancer

A pilot study is assessing the safety and tolerability of dapagliflozin in patients with high-risk prostate cancer prior to surgery.

ClinicalJune 30, 2026

Dana-Farber initiates CV Care program for prostate cancer patients on ADT

The CV Care program aims to assess and manage cardiovascular risk factors in prostate cancer patients undergoing androgen deprivation therapy.

ClinicalJune 30, 2026

Phase II Trial of Dose-Escalated MR-Guided Radiotherapy for Prostate Cancer Initiated

A multi-centre randomized trial is underway to evaluate the safety and efficacy of dose-escalated MR-guided radiotherapy for localized prostate cancer.

RegulatoryJune 28, 2026

Capivasertib plus Abiraterone Approved for PTEN-Deficient Prostate Cancer

The FDA approved the combination of capivasertib with abiraterone acetate for PTEN-deficient metastatic castration-sensitive prostate cancer, based on improved progression-free survival.

ClinicalJune 28, 2026

Phase 2 Trial of SX-682 and Docetaxel in Advanced Head and Neck and Prostate Cancers

A new trial is underway to evaluate the combination of SX-682 and docetaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma and advanced prostate cancer.

ClinicalJune 27, 2026

Study Aims to Enhance Minority Representation in Prostate Cancer Trials

A study led by M.D. Anderson Cancer Center is addressing the lack of representation of racial and ethnic minorities in prostate cancer clinical trials.

ClinicalJune 26, 2026

Bayer's Study on Darolutamide in Japanese Men with Low-Volume mHSPC

Bayer is conducting an observational study to assess the safety and efficacy of darolutamide combined with ADT and docetaxel in Japanese men with low-volume metastatic hormone-sensitive prostate cancer.

ClinicalJune 25, 2026

miR-6833-3p Promotes Prostate Cancer Progression via NUMB-NOTCH Pathway Inhibition

miR-6833-3p drives prostate cancer progression by inhibiting the NUMB-mediated NOTCH signaling pathway.

ClinicalJune 23, 2026

Novel PSMA-targeted Imaging and SABR for Recurrent Prostate Cancer

A clinical trial is investigating the use of PSMA-targeted PET imaging combined with MR imaging to localize recurrent prostate cancer for targeted stereotactic ablative radiotherapy.

RegulatoryJune 22, 2026

FDA approves capivasertib with abiraterone for PTEN-deficient prostate cancer

Capivasertib has been approved by the FDA for use with abiraterone and prednisone in treating PTEN-deficient metastatic prostate cancer.

ClinicalJune 21, 2026

Ubiquitination signature identified in neuroendocrine prostate cancer with therapeutic implications

A ubiquitination-centered signature linked to neuroendocrine prostate cancer (NEPC) was identified, highlighting its role in lineage plasticity.

ClinicalJune 19, 2026

Amgen's Xaluritamig Plus Abiraterone Trial Targets Metastatic Prostate Cancer

Amgen is conducting a trial to compare overall survival in patients with metastatic castration-resistant prostate cancer receiving xaluritamig plus abiraterone versus standard treatments.

ClinicalJune 18, 2026

Phase Ib/II Trial of QLC5508 and QLH12016 in Advanced Prostate Cancer

A Phase Ib/II clinical trial is underway to evaluate QLC5508 and QLH12016 in combination with other therapies for advanced prostate cancer.

ClinicalJune 17, 2026

Study on Exercise Program's Impact on Quality of Life in Prostate Cancer Patients

A clinical trial is assessing the effects of a structured exercise program on quality of life and health outcomes in prostate cancer patients.

ClinicalJune 17, 2026

Gut Microbiota Impairs Flutamide Efficacy in Prostate Cancer Treatment

Gut bacteria metabolize Flutamide into inactive forms, reducing its therapeutic efficacy against prostate cancer.

ClinicalJune 17, 2026

Trial Evaluates Pelvic Radiotherapy with ADT in Node Positive Prostate Cancer

A clinical trial is assessing the efficacy of adding pelvic radiotherapy to androgen deprivation therapy in patients with node-positive prostate cancer post-prostatectomy.

RegulatoryJune 16, 2026

Truqap approved in US for PTEN-deficient metastatic prostate cancer

Truqap, a first-in-class AKT inhibitor, has been approved in the US for treating PTEN-deficient metastatic hormone-sensitive prostate cancer.

RegulatoryJune 16, 2026

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

The FDA ODAC has recommended Truqap in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer.

ClinicalJune 16, 2026

TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer

The Phase 3 TALAPRO-3 study demonstrated that TALZENNA plus XTANDI significantly improved radiographic progression-free survival (rPFS) by 52% in patients with HRR gene-altered metastatic prostate cancer.

RegulatoryJune 13, 2026

Roche's VENTANA PTEN Assay Receives FDA Approval for Prostate Cancer Companion Diagnostic

Roche's VENTANA PTEN (SP218) RxDx Assay is the first FDA-approved companion diagnostic for assessing PTEN protein loss in prostate cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Head and Neck Cancer →

Prostate Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.